AAAAAA
Results: 26-32/32
Authors:
BOOT H
VANHEERDE P
DEJONG D
SOMERS R
BURGERS JVM
VANCOEVORDEN F
TAAL BG
Citation: H. Boot et al., GASTRIC LYMPHOMA - CAN TREATMENT ADEQUACY EXPLAIN OUTCOME, Gastroenterology, 108(4), 1995, pp. 450-450
Authors:
TAAL BG
ALEMAN BMP
BOOT H
SCHAAKEKONING CCE
Citation: Bg. Taal et al., COMPLICATIONS AND SIDE-EFFECTS OF HIGH-DOSE-RATE (HDR) INTRALUMINAL BRACHYTHERAPY PLUS EXTERNAL-BEAM IRRADIATION IN ESOPHAGEAL CANCER, Gastroenterology, 108(4), 1995, pp. 543-543
Authors:
TAAL BG
ALEMAN BMP
BOOT H
SCHAAKEKONING CCE
Citation: Bg. Taal et al., TREATMENT MODALITIES USING HIGH-DOSE-RATE (HDR) INTRALUMINAL IRRADIATION FOR ESOPHAGEAL CANCER, Gastroenterology, 108(4), 1995, pp. 543-543
Authors:
TAAL BG
HOEFNAGEL CA
OLMOS RAV
BOOT H
Citation: Bg. Taal et al., THE PALLIATIVE EFFECT OF METAIODOBENZYLGUANIDINE (MIBG) IN THE CARCINOID-SYNDROME, Gastroenterology, 108(4), 1995, pp. 543-543
Authors:
TAAL BG
BEIJNEN JH
TELLER FGM
HUININK WWT
DUBBELMAN R
BOOT H
Citation: Bg. Taal et al., BIOAVAILABILITY OF ORAL ETOPOSIDE IN GASTRIC-CANCER, European journal of cancer, 30A(3), 1994, pp. 420-421
Authors:
TAAL BG
TELLER FGM
HUININK WWT
BOOT H
BEIJNEN JH
DUBBELMAN R
Citation: Bg. Taal et al., ETOPOSIDE, LEUCOVORIN, 5-FLUOROURACIL (ELF) COMBINATION CHEMOTHERAPY FOR ADVANCED GASTRIC-CANCER - EXPERIENCE WITH 2 TREATMENT SCHEDULES INCORPORATING INTRAVENOUS OR ORAL ETOPOSIDE, Annals of oncology, 5(1), 1994, pp. 90-92
Authors:
OLMOS RAV
TAAL BG
HOEFNAGEL CA
BOOT H
Citation: Rav. Olmos et al., SE-75HCAT IN THE ASSESSMENT OF IMPROVED BILE-ACID ABSORPTION IN PATIENTS WITH ILEAL DAMAGE BY DELAYING BOWEL MOTILITY WITH LOPERAMIDE, European journal of gastroenterology & hepatology, 5(11), 1993, pp. 941-945